Bristol-Myers Squibb funds global RandD in virology; Russian researchers may seek grant support

Bristol-Myers Squibb, a pharmaceutical multinational, has announced a grant program to support RandD in the field of chronic viral disease therapy, including the HIV and B- and C-type chronic hepatitis.

Bristol-Myers Squibb, a pharmaceutical multinational, has launched Partnering for Cure, a grant program to support R&D in the field of chronic viral disease therapy, including the HIV and B- and C-type chronic hepatitis, Rusnanonet.ru reported. The company is said to have plans to provide up to 200,000 euro grants for virology research to last as long as two years. An application for a grant is expected to contain an original and innovative research idea. All applications will be assessed by an international panel of experts representing clinical and scientific circles from several European countries, including Germany, France, Switzerland, Sweden, Belgium, Italy, Spain, and Great Britain...